https://www.selleckchem.com/pr....oducts/pd-1-pd-l1-in
however, there was a clear separation between mucosal and fecal overall samples CONCLUSIONS We report fungal dysbiosis in children with CeD, suggesting a possible role in the pathogenesis of CeD. Further larger, controlled, prospective and longitudinal studies are needed to verify the results of this study and clarify the functional role of fungi in CeD. Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial
Mi piace
Commento
Condividi
